Premium
Payers and the Assessment of Clinical Utility for Companion Diagnostics
Author(s) -
Quinn B
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.234
Subject(s) - reimbursement , scrutiny , clinical pharmacology , health care , medicine , payment , companion diagnostic , diagnostic test , intensive care medicine , medical physics , business , pharmacology , political science , pediatrics , law , finance , cancer
The decision makers who approve or deny payment for health‐care services review many new technologies. Reimbursement for companion diagnostics for expensive drugs (“personalized medicine”) is already under close policy scrutiny, in line with long‐standing concerns about overuse of diagnostic tests. Evaluation of diagnostic tests adds some complexities to the payer's comparative‐effectiveness evaluation for drugs alone. Currently, decision‐making frameworks suitable for companion diagnostics are being developed for practical application by payer policy makers. Clinical Pharmacology & Therapeutics (2010) 88 6, 751–754. doi: 10.1038/clpt.2010.234